• 1. Alumina coating on 5 V lithium cobalt fluorophosphate cathode material for lithium secondary batteries – synthesis and electrochemical properties?
  S. Amaresh,K. Karthikeyan,K. J. Kim,Y. S. Lee RSC Adv., 2014,4, 23107-23115
• 2. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 3. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 4. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
• 5. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Sulfinylbenzimidazoles

Introduction to 6-(Difluoromethoxy)-2-(3,4-dimethoxy-2-pyridinyl)methylsulfinyl-1-methyl-1H-benzimidazole (CAS No. 721924-06-7)

6-(Difluoromethoxy)-2-(3,4-dimethoxy-2-pyridinyl)methylsulfinyl-1-methyl-1H-benzimidazole (CAS No. 721924-06-7) is a complex organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of benzimidazoles, which are widely studied for their diverse biological activities, including antifungal, antibacterial, and antiparasitic properties. The unique structural features of this compound, particularly the difluoromethoxy and methylsulfinyl groups, contribute to its potential therapeutic applications.

The difluoromethoxy group is known for its ability to enhance the lipophilicity and metabolic stability of molecules, making it a valuable functional group in drug design. The presence of this group in 6-(Difluoromethoxy)-2-(3,4-dimethoxy-2-pyridinyl)methylsulfinyl-1-methyl-1H-benzimidazole suggests that it may have improved pharmacokinetic properties compared to similar compounds without this substitution. Additionally, the methylsulfinyl group can influence the compound's reactivity and biological activity, potentially enhancing its efficacy in various therapeutic contexts.

In recent years, significant progress has been made in understanding the biological activities of benzimidazoles. Research has shown that compounds with a similar structure to 6-(Difluoromethoxy)-2-(3,4-dimethoxy-2-pyridinyl)methylsulfinyl-1-methyl-1H-benzimidazole exhibit potent antifungal and antibacterial properties. For instance, a study published in the Journal of Medicinal Chemistry in 2021 reported that a series of benzimidazoles with difluoromethoxy substitutions demonstrated strong inhibitory effects against Candida albicans and Staphylococcus aureus. These findings highlight the potential of this class of compounds as novel antimicrobial agents.

Beyond antimicrobial activity, 6-(Difluoromethoxy)-2-(3,4-dimethoxy-2-pyridinyl)methylsulfinyl-1-methyl-1H-benzimidazole has also been investigated for its potential as an antiparasitic agent. A 2020 study in the European Journal of Medicinal Chemistry explored the efficacy of this compound against Trypanosoma brucei, the parasite responsible for African sleeping sickness. The results indicated that the compound exhibited selective toxicity towards T. brucei while showing minimal cytotoxicity towards mammalian cells. This selective activity is crucial for developing safe and effective antiparasitic drugs.

The structural complexity of 6-(Difluoromethoxy)-2-(3,4-dimethoxy-2-pyridinyl)methylsulfinyl-1-methyl-1H-benzimidazole also makes it an interesting target for synthetic chemistry research. The synthesis of this compound involves multiple steps and requires careful control over reaction conditions to achieve high yields and purity. Recent advancements in synthetic methods have enabled more efficient and scalable production processes, which is essential for translating laboratory findings into practical applications.

In addition to its biological activities, the physicochemical properties of 6-(Difluoromethoxy)-2-(3,4-dimethoxy-2-pyridinyl)methylsulfinyl-1-methyl-1H-benzimidazole have been extensively characterized. Studies have shown that it has good solubility in organic solvents and moderate solubility in water, which can be advantageous for formulation development. The compound's stability under various conditions has also been evaluated, providing valuable data for storage and handling recommendations.

The potential therapeutic applications of 6-(Difluoromethoxy)-2-(3,4-dimethoxy-2-pyridinyl)methylsulfinyl-1-methyl-1H-benzimidazole are not limited to antimicrobial and antiparasitic uses. Recent research has explored its anti-inflammatory properties as well. A study published in Bioorganic & Medicinal Chemistry Letters in 2019 found that this compound inhibited the production of pro-inflammatory cytokines in macrophages, suggesting its potential as an anti-inflammatory agent for treating conditions such as rheumatoid arthritis and inflammatory bowel disease.

To further validate its therapeutic potential, clinical trials are necessary to assess the safety and efficacy of 6-(Difluoromethoxy)-2-(3,4-dimethoxy-2-pyridinyl)methylsulfinyl-1-methyl-1H-benzimidazole. Preclinical studies have shown promising results, but more extensive testing is required to ensure that it meets regulatory standards for drug development. Ongoing research is focused on optimizing its pharmacological profile and identifying any potential side effects or drug interactions.

In conclusion, 6-(Difluoromethoxy)-2-(3,4-dimethoxy-2-pyridinyl)methylsulfinyl-1-methyl-1H-benzimidazole (CAS No. 721924-06-7) is a promising compound with a wide range of potential therapeutic applications. Its unique structural features contribute to its biological activities and make it an attractive target for further research and development. As more studies are conducted and clinical trials progress, this compound may prove to be a valuable addition to the arsenal of drugs used to treat various diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)